LivaNova’s (LIVN) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of LivaNova (NASDAQ:LIVN) in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a $75.00 price objective on the stock.

Several other research analysts have also recently issued reports on the company. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 23rd. The Goldman Sachs Group began coverage on LivaNova in a report on Friday, October 4th. They set a “buy” rating and a $65.00 price objective on the stock. Robert W. Baird lifted their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $69.17.

LivaNova Stock Down 0.2 %

LIVN stock opened at $50.64 on Tuesday. LivaNova has a 52 week low of $43.15 and a 52 week high of $64.47. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of 120.57 and a beta of 1.01. The firm’s 50-day moving average is $49.05 and its two-hundred day moving average is $49.97. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Insiders Place Their Bets

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LIVN. Atria Investments Inc lifted its holdings in LivaNova by 6.2% in the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after purchasing an additional 331 shares during the last quarter. State of Alaska Department of Revenue lifted its position in shares of LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares during the last quarter. Central Pacific Bank Trust Division boosted its stake in LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after purchasing an additional 720 shares during the period. Rhumbline Advisers increased its position in LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock worth $8,240,000 after acquiring an additional 899 shares during the period. Finally, AQR Capital Management LLC raised its position in shares of LivaNova by 0.7% during the second quarter. AQR Capital Management LLC now owns 129,871 shares of the company’s stock valued at $7,103,000 after buying an additional 930 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.